TuHURA Biosciences, Inc. HURA
TuHURA Biosciences, Inc. (Nasdaq: HURA) is an oncology drug developer. Its lead program, IFx-2.0, is in Phase 3 for first-line advanced/metastatic Merkel cell carcinoma, with pembrolizumab. Its next catalyst on record is TBS-2025: Phase 1b/2 trial with menin inhibitor in mutNPM1 AML (planned) (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TBS-2025 — Phase 1b/2 trial with menin inhibitor in mutNPM1 AML (planned) (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IFx-2.0 | Merkel cell carcinoma | biologic-other | Phase 3 |
| TBS-2025 (VISTA antibody) | mutNPM1 AML | antibody | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.